Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk

Obesity

Volumn 16, Issue 2, 2008, Pages 339-347

  Slattery, Martha L ^a   Curtin, Karen ^a   Sweeney, Carol ^a   Wolff, Roger K ^a   Baumgartner, Richard N ^b   Baumgartner, Kathy B ^b   Giuliano, Anna R ^c,e   Byers, Tim ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BODY MASS; BODY SIZE; BREAST TUMOR; CAUCASIAN; COMPARATIVE STUDY; ETHNOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; MIDDLE AGED; OBESITY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; WAIST HIP RATIO; WEIGHT GAIN;

ADIPOSITY; ADULT; AGED; BODY MASS INDEX; BODY SIZE; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HISPANIC AMERICANS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SOUTHWESTERN UNITED STATES; WAIST-HIP RATIO; WEIGHT GAIN;

EID: 39449125021     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.44     Document Type: Article

References (38)

1. Miller, W.R. Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer. Seminars in Oncology 2003;30:3-11.
2. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001;10:15-32.
3. Stoll BA. Timing of weight gain in relation to breast cancer risk. Ann Oncol 1995;6:245-248.
4. Slattery ML, Sweeney C, Edwards S et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 2006;102:85-101.
5. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-1788.
6. White MF. Insulin signaling in health and disease. Science 2003;302:1710-1711.
7. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
8. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003;88:255-259.
9. Bennermo M, Held C, Stemme S et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem 2004;50:2136-2140.
10. Mohlig M, Boeing H, Spranger J et al. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab 2004;89:1885-1890.
11. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-233.
12. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005;65:10637-10641.
13. Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007;8:279-287.
14. Slattery ML, Curtin K, Baumgartner R et al. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern united states. Cancer Epidemiol Biomarkers Prev 2007;16:747-755.
15. Howard CA, Samet JM, Buechley RW, Schrag SD, Key CR. Survey research in New Mexico hispanics: some methodological issues. Am J Epidemiol 1983;117:27-34.
16. Ainsworth BE, Haskell WL, Whitt MC et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32:S498-S504.
17. Ainsworth BE, Irwin ML, Addy CL, Whitt MC, Stolarczyk LM. Moderate physical activity patterns of minority women: the Cross-Cultural Activity Participation Study. J Womens Health Gend Based Med 1999 8:805-813.
18. Slattery ML, Edwards S, Murtaugh MA et al. Physical activity and breast cancer risk among women in the southwestern United States. Ann Epidemiol 2007;17:342-353.
19. Watanabe E, Hirasawa H, Oda S et al. Extremely high interleukin-6 blood levels and outcome In the critically ill are associated with tumor necrosis factor- and interleukin-1 -related gene polymorphisms. Crit Care Med 2005;33:89-97; discussion 242-243.
20. Sweeney C, Wolff RK, Byers T et al. Genetic admixture among Hispanics and candidate gene polymorphisms: potential for confounding in a breast cancer study? Cancer Epidemiol Biomarkers Prev 2007;16:142-150.
21. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-927.
22. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995;56:799-810.
23. Stram DO, Leigh Pearce C, Bretsky P et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55:179-190.
24. Haiman CA, Stram DO, Pike MC et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the multiethnic cohort. Hum Mol Genet 2003;12:2679-2692.
25. Sweeney C, Curtin K, Murtaugh MA, Caan BJ, Potter JD, Slattery ML. Haplotype analysis of common vitamin D receptor variants and colon and rectal cancers. Cancer Epidemiol Biomarkers Prev 2006;15: 744-749.
26. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998;22:1145-1158.
27. Huth C, Heid IM, Vollmert C et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006;55:2915-2921.
28. Judson R, Brain C, Dain B, Windemuth A, Ruano G, Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004;177:345-351.
29. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376.
30. Klipstein-Grobusch K, Mohlig M, Spranger J et al. Interleukin-6g.-174G>C promoter polymorphism is associated with obesity in the EPIC-Potsdam Study. Obesity (Sliver Spring) 2006;14:14-18.
31. Berthier MT, Paradis AM, Tchernof A et al. The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet 2003;48:14-19.
32. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000;275:18138-18144.
33. Purohit A, Ghilchik MW, Duncan L et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 1995;80:3052-3058.
34. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust 2006;185:445-449.
35. Festa A, D'Agostino, R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
36. Schmidt Ml, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-1652.
37. Pradhan AD, Cook NR, Burlng JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vase Biol 2003;23:650-655.
38. Kubaszek A, Pihlajamaki J, Komarovski V et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003;52:1872-1876.